Skip to main content
. Author manuscript; available in PMC: 2010 Sep 29.
Published in final edited form as: J Neuroimmunol. 2009 Aug 6;214(1-2):67–77. doi: 10.1016/j.jneuroim.2009.06.023

Figure 6.

Figure 6

GPR30 agonist treatment reduced CNS macrophage accumulation. SJL mice (5–7 weeks old) were immunized s.c. with 50 μg PLP139-151 and CFA (400 μg Mycobacterium tuberculosis). Mice were treated with 50 mg/kg/day G-1 daily for 21 days beginning at the day of disease induction. Control mice were similarly treated with vehicle (5% DMSO, 95% PEG-300). When the control mice showed peak clinical disease (Figure 5), CNS was harvested from three representative mice in each of the control (disease scores=3, 3, 2) and G-1-treated (disease scores=1, 1, 1) groups. Leukocyte subpopulations were examined in each individual mouse by flow cytometry. The data show a decrease in CD45hiCD11b+ macrophage percentages in the CNS of G-1-treated mice. The data are representative of two similar, independent experimental replicates.